Menu Back toClosing-Session-Panel-Discussion

DIA/FDA Oligonucleotide-Based Therapeutics Conference


Closing Session: Panel Discussion

Session Chair(s)

Arthur A. Levin, PhD

Arthur A. Levin, PhD

  • Executive Vice President, Research and Development
  • Avidity Biosciences , United States
Closing Session: Panel Discussion

Speaker(s)

Paul C. Brown, PhD

Panelist

Paul C. Brown, PhD

  • ODE Associate Director for Pharmacology and Toxicology, OND, CDER
  • FDA, United States
Scott  Henry, PhD

Panelist

Scott Henry, PhD

  • Vice President, Nonclinical Development
  • Ionis Pharmaceuticals, Inc., United States
René  Thürmer, PhD

Panelist

René Thürmer, PhD

  • Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
  • Federal Institute for Drugs and Medical Devices, Germany
G. Susan  Srivatsa, PhD

Panelist

G. Susan Srivatsa, PhD

  • President
  • ElixinPharma, United States
Hobart  Rogers, PharmD, PhD

Panelist

Hobart Rogers, PharmD, PhD

  • Pharmacologist
  • FDA, United States
Saraswathy V. Nochur, PhD, MSc

Panelist

Saraswathy V. Nochur, PhD, MSc

  • Chief Regulatory Officer
  • Alnylam Pharmaceuticals, United States